Evidence map›Paper›PMID 37945668›Full record

ArticleScientific reports2023

An effective method for culturing functional human corneal endothelial cells using a xenogeneic free culture medium.

S Alonso-Alonso, N Vázquez, M Chacón, N Caballero-Sánchez, S Del Olmo-Aguado, C Suárez, B Alfonso-Bartolozzi, L Fernández-Vega-Cueto, L Nagy, J Merayo-Lloves and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

S Alonso-AlonsoInstituto Universitario Fernández-Vega, Fundación de Investigación Oftalmológica, Universidad de Oviedo, Avenida Doctores Fernández Vega, 33012, Oviedo, Asturias, Spain.
N VázquezInstituto Universitario Fernández-Vega, Fundación de Investigación Oftalmológica, Universidad de Oviedo, Avenida Doctores Fernández Vega, 33012, Oviedo, Asturias, Spain. natalia.vazquez@fio.as.
M ChacónInstituto Universitario Fernández-Vega, Fundación de Investigación Oftalmológica, Universidad de Oviedo, Avenida Doctores Fernández Vega, 33012, Oviedo, Asturias, Spain.
N Caballero-SánchezDoctoral School of Molecular Cell and Immunobiology. Faculty of Medicine, University of Debrecen, Nagyerdei Krt, Debrecen, 4032, Hungary.
S Del Olmo-AguadoInstituto Universitario Fernández-Vega, Fundación de Investigación Oftalmológica, Universidad de Oviedo, Avenida Doctores Fernández Vega, 33012, Oviedo, Asturias, Spain.
C SuárezInstituto Universitario Fernández-Vega, Fundación de Investigación Oftalmológica, Universidad de Oviedo, Avenida Doctores Fernández Vega, 33012, Oviedo, Asturias, Spain.
B Alfonso-BartolozziInstituto de Investigación Sanitaria del Principado de Asturias (ISPA), Avenida del Hospital Universitario, 33011, Oviedo, Asturias, Spain.
L Fernández-Vega-CuetoInstituto de Investigación Sanitaria del Principado de Asturias (ISPA), Avenida del Hospital Universitario, 33011, Oviedo, Asturias, Spain.
L NagyDepartment of Biochemistry and Molecular Biology, Nuclear Receptor Research Laboratory, Faculty of Medicine, University of Debrecen, Nagyerdei Krt, Debrecen, 4032, Hungary.
J Merayo-LlovesInstituto Universitario Fernández-Vega, Fundación de Investigación Oftalmológica, Universidad de Oviedo, Avenida Doctores Fernández Vega, 33012, Oviedo, Asturias, Spain.
A MeanaInstituto Universitario Fernández-Vega, Fundación de Investigación Oftalmológica, Universidad de Oviedo, Avenida Doctores Fernández Vega, 33012, Oviedo, Asturias, Spain.
Instituto de Investigación Sanitaria del Principado de Asturias · ESUniversity of Debrecen · HUFernández-Vega Ophthalmological Institute · ESUniversidad de Oviedo · ES

Funding

DHA-derived resolvin production andsignaling in tissue repair macrophages in metabolic diseaseR01DK124782 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI NAGY, LASZLO, SPITE, MATTHEW R · 2020 to 2023
$2.3M
PPARgamma as an architectural regulator of gene expression in endocrine signalingR01DK115924 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI NAGY, LASZLO · 2018 to 2021
$1.6M
NIDDK NIH HHS R01 DK115924NIDDK NIH HHS R01 DK124782
6 · The paper itself

Abstract

Endothelial dysfunction is a leading cause of corneal blindness in developed countries and the only available treatment is the endothelial transplantation. However, the limited availability of suitable donors remains a significant challenge, driving the exploration of alternative regenerative therapies. Advanced Therapy Medicinal Products show promise but must adhere to strict regulations that prohibit the use of animal-derived substances. This study investigates a novel culture methodology using Plasma Rich in Growth Factors (PRGF) as the only source of growth factors for primary cultures of human corneal endothelial cells (CECs). CECs were obtained from discarded corneas or endothelial rings and cultured in two different media: one supplemented with xenogeneic factors and other xenogeneic-free, using PRGF. Comprehensive characterization through immunofluorescence, morphological analyses, trans-endothelial electrical resistance measurements, RNA-seq, and qPCR was conducted on the two groups. Results demonstrate that CECs cultured in the xenogeneic-free medium exhibit comparable gene expression, morphology, and functionality to those cultured in the xenogeneic medium. Notably, PRGF-expanded CECs share 46.9% of the gene expression profile with native endothelium and express all studied endothelial markers. In conclusion, PRGF provides an effective source of xenogeneic-free growth factors for the culture of CECs from discarded corneal tissue. Further studies will be necessary to demonstrate the applicability of these cultures to cell therapies that make clinical translation possible.

Indexed as

Endothelial CellsEndothelium, CornealAnimalsCell- and Tissue-Based TherapyCells, CulturedCorneaHumans

Identifiers

PMID37945668
PMCPMC10636196
OpenAlexW4388540295

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.